#1 Clinical Trials Search in Europe
EU – Europe
AT – Austria
HR – Croatia
CZ – Czech Republic
DK – Denmark
EE – Estonia
FI – Finland
FR – France
DE – Germany
IS – Iceland
IT – Italy
LV – Latvia
LT – Lithuania
NL – Netherlands
NO – Norway
PL – Poland
PT – Portugal
RO – Romania
SK – Slovakia
SI – Slovenia
ES – Spain
SE – Sweden
  • Find a Clinical Trial

    Search Trials by Disease

    Non-small cell lung cancer Breast cancer Plasma cell myeloma Neoplasm Acute myeloid leukaemia Neoplasm malignant Colitis ulcerative Obesity Colorectal cancer metastatic Prostate cancer Crohn's disease Colorectal cancer Ovarian cancer Hepatocellular carcinoma Dementia Alzheimer's type Asthma Dermatitis atopic Breast cancer metastatic Non-small cell lung cancer metastatic Malignant melanoma More trials…
  • Rare Diseases Treatments

    Search Trials by Disease

    Systemic candida Inborn error of metabolism B-cell small lymphocytic lymphoma recurrent Richter's syndrome Arrhythmia Pyruvate dehydrogenase complex deficiency Toxic epidermal necrolysis Bronchiectasis Wolfram syndrome ABO haemolytic disease of newborn Acute graft versus host disease in liver Penile cancer Cognitive disorder Hormone-dependent prostate cancer Myasthenia gravis More trials…

    Learn about Rare Diseases

    Small intestine leiomyosarcoma – Trials in Disease Mantle cell lymphoma stage II – Trials in Disease Lysosomal storage disorder – Diagnostics Medulloblastoma – Life with Disease Glycogen storage disease type II – Basic Information Congenital nephrogenic diabetes insipidus – Treatment Marfan’s syndrome – Diagnostics Pemphigoid Leiomyosarcoma metastatic – Treatment Mucous membrane pemphigoid – Basic Information More diseases
  • Vaccine Clinical Trials
  • Pediatric Clinical Trials
  • Resources for Patients

    Browse Innovative Treatments

    Ficlatuzumab Keto-Valine Calcium WEF-001 4-IODOPHENYLALANINE I-131 Emrusolmin MRNA-1345 Anhydrous Caffeine ZINC GLUCONATE Nicotinamide Vidofludimus Calcium Valaciclovir Orismilast Indacaterol Maleate Propylene Glycol RNMB3 Eptacog Beta (Activated) RP3 Finerenone Asp1570 Nandrolone Decanoate More therapies…

    Learn about Your Condition

    Primary myelofibrosis Hepatic neoplasm Pituitary tumour benign Coronary artery occlusion Atrophic vulvovaginitis Seasonal allergy Hypotonia Synovial sarcoma metastatic Psoriatic arthropathy Hypotransferrinaemia Tumour of ampulla of Vater Polycystic liver disease Pancreatic carcinoma Stem cell transplant Thrombosis prophylaxis More diseases
  • Healthy Volunteers
  • Patient Guide
  • Our Partners
  • About Us
  • Contact us
  • Region
    🇪🇺 Europe
    🇦🇹 Austria
    🇭🇷 Croatia
    🇨🇿 Czech Republic
    🇩🇰 Denmark
    🇪🇪 Estonia
    🇫🇮 Finland
    🇫🇷 France
    🇩🇪 Germany
    🇮🇸 Iceland
    🇮🇹 Italy
    🇱🇻 Latvia
    🇱🇹 Lithuania
    🇳🇱 Netherlands
    🇳🇴 Norway
    🇵🇱 Poland
    🇵🇹 Portugal
    🇷🇴 Romania
    🇸🇰 Slovakia
    🇸🇮 Slovenia
    🇪🇸 Spain
    🇸🇪 Sweden

PIK3CA related overgrowth spectrum

  • Study of alpelisib in children and adults with PIK3CA-Related Overgrowth Spectrum (PROS)

    Recruiting

    2 1 1
    Investigated Diseases:
    • PIK3CA related overgrowth spectrum
    Investigated Drugs:
    • Alpelisib
    Austria Belgium France Germany Italy The Netherlands +1

  • Study of RLY-2608 for Adults and Children with PIK3CA-Related Overgrowth and Malformations

    Recruiting

    2 1 1
    Investigated Diseases:
    • Lymphatic malformation
    • PIK3CA-activated mutation
    • PIK3CA related overgrowth spectrum
    Investigated Drugs:
    • RLY-2608
    Belgium France Germany Ireland Italy Norway +1

  • Study on the Effects and Safety of Alpelisib for Children and Adults with Megalencephaly-Capillary Malformation Polymicrogyria Syndrome

    Recruiting

    2 1 1
    Investigated Diseases:
    • PIK3CA related overgrowth spectrum
    Investigated Drugs:
    • Alpelisib
    France

  • Study of alpelisib in children and adults with PIK3CA-Related Overgrowth Spectrum (PROS)

    Not recruiting

    2 1
    Investigated Drugs:
    • Alpelisib
    France Germany Italy The Netherlands Norway Spain

  • Study on the Long-Term Safety of Alpelisib for Patients with PIK3CA-Related Overgrowth Spectrum (PROS)

    Not recruiting

    2 1 1
    Investigated Diseases:
    • PIK3CA related overgrowth spectrum
    Investigated Drugs:
    • Alpelisib
    France Ireland Spain

  • Long-term Safety Study of Miransertib for Patients with PIK3CA-related Overgrowth Spectrum or Proteus Syndrome

    Not recruiting

    2 1 1
    Investigated Diseases:
    • Proteus syndrome
    • PIK3CA related overgrowth spectrum
    Investigated Drugs:
    • Miransertib
    Italy

Investigational Drugs in This Location

See which drug candidates are part of clinical trials near you. Click for detailed trial information.

Medical Conditions Being Studied in This Location

Explore diseases currently included in clinical trials near you. Click to view trials and details for each condition.

European Clinical Trials Information Network

The European Clinical Trials Information Network is transforming access to clinical trial information for patients across Europe. By overcoming language barriers, our platform allows everyone, regardless of their native language, to easily find relevant and comprehensible clinical trial data. This innovative service connects patients to cutting-edge treatments, creating a unified European community where health and progress transcend borders.

This service is not affiliated with the European Commission, the EMA, or the official CTIS system. Most information comes from publicly available international clinical-trial registries, supplemented by data from academic centres, national regulators, and commercial sponsors. We aim to keep all content accurate and up to date.

Explore the full ecosystem of clinical research in Europe.

The information provided on this website is mainly derived from international public clinical trial databases (CTIS.eu). In addition, we are including supplementary sources, such as information provided by academic centers and national regulators, as well as information supplied by commercial sponsors (pharmaceutical companies and contract research organizations). We try to ensure that the information provided is accurate and up to date.

Certain content and visual elements on this website have been generated or enhanced using artificial intelligence (AI).

The website is published by:
CTIN POLAND sp. z o.o.
with its registered office in Warsaw,
ul. rtm. Witolda Pileckiego 67/109,
02-781 Warsaw, Poland,
entered in the Register of Entrepreneurs of the National Court Register under KRS number 0001111334,
REGON: 528919042, NIP (Tax ID): 9512598637
Contact us

© 2026 CTIN Poland

Privacy Policy

Terms and Conditions

Contact

For Sites and Sponsors

Clinical Trial Locations

We use cookies

The website uses cookies to ensure the proper functioning of the site and to analyze internet traffic. Some cookies are essential for using the service and do not require consent. You can accept all cookies or use only the essential ones. Data is processed in accordance with our Privacy Policy. You have the right to withdraw your consent, access, rectify, delete, or limit the processing of your data at any time.
Numer nieprawidłowy!
Numer nieprawidłowy!